Patents Assigned to Arrowhead Research Corporation
  • Patent number: 9371529
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: June 21, 2016
    Assignee: Arrowhead Research Corporation
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • Patent number: 9347062
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: May 24, 2016
    Assignee: Arrowhead Research Corporation
    Inventors: Ying Yu, Jon E. Chatterton
  • Patent number: 9289514
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: March 22, 2016
    Assignee: Arrowhead Research Corporation
    Inventor: Jon E. Chatterton
  • Patent number: 9233170
    Abstract: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: January 12, 2016
    Assignee: Arrowhead Research Corporation
    Inventor: Jon E. Chatterton
  • Publication number: 20150376621
    Abstract: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2?-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2?-Fluorine. The invention provides that the 2?-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide “TT” sequence at the 3? end of the molecule.
    Type: Application
    Filed: May 14, 2015
    Publication date: December 31, 2015
    Applicant: ARROWHEAD RESEARCH CORPORATION
    Inventors: Jang HAN, Michael HOUGHTON
  • Patent number: 9206428
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: December 8, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • Patent number: 9173896
    Abstract: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: November 3, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jon E. Chatterton, Abbot F. Clark, Martin B. Wax
  • Patent number: 9150862
    Abstract: Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: October 6, 2015
    Assignees: Thermo Fisher Scientific Inc., Arrowhead Research Corporation
    Inventors: Anja Smith, Angela Reynolds, Jon E. Chatterton, Xinyu Zhang
  • Patent number: 9139833
    Abstract: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: September 22, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jang Han, Mi-Young Seo, Michael Houghton
  • Patent number: 9139834
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: September 22, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jon E. Chatterton, Abbot F. Clark, David P. Bingaman, Martin B. Wax, Adrian M. Timmers
  • Patent number: 9133462
    Abstract: The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: September 15, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Mark Aron Labow, Larry Alexander Gaither, Jason Borawski
  • Patent number: 9114152
    Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: August 25, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jon E. Chatterton, Abbot F. Clark
  • Patent number: 9096637
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: August 4, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
  • Patent number: 9084808
    Abstract: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2?-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2?-Fluorine. The invention provides that the 2?-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide “TT” sequence at the 3? end of the molecule.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: July 21, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Jang Han, Michael Houghton
  • Patent number: 9080175
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 14, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Antonin De Fougerolles, John L. Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Patent number: 9074212
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: July 7, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans Peter Vornlocher
  • Patent number: 8946176
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: February 3, 2015
    Assignee: Arrowhead Research Corporation
    Inventors: John Frederick Boylan, Birgit Bramlage, Markus Hossbach, John Reidhaar-Olson
  • Publication number: 20130079383
    Abstract: The invention relates to the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein n, G, W, X, Y, and R1 are defined in the detailed description and claims. The compounds of formula I bind to or associate with VLA-4 and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing VLA-4.
    Type: Application
    Filed: July 5, 2012
    Publication date: March 28, 2013
    Applicant: ARROWHEAD RESEARCH CORPORATION
    Inventors: John Frederick BOYLAN, Robert A. GOODNOW, Wei HE, Tai-An LIN, Achyutharao SIDDURI
  • Publication number: 20130072543
    Abstract: The invention relates to compositions containing compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, and n are defined in the detailed description and claims. In addition, the present invention relates to novel formulations containing compounds of formula I for improved delivery of nucleic acids such as siRNA to the cytoplasm of target cells. In particular embodiments these formulations comprise compounds of formula I, phospholipids, cholesterol, and pegylated lipids. The present invention also relates to methods of manufacturing and using such compounds and compositions.
    Type: Application
    Filed: July 5, 2012
    Publication date: March 21, 2013
    Applicant: ARROWHEAD RESEARCH CORPORATION
    Inventors: John Frederick Boylan, Wei He
  • Publication number: 20130005793
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.
    Type: Application
    Filed: June 28, 2012
    Publication date: January 3, 2013
    Applicant: ARROWHEAD RESEARCH CORPORATION
    Inventors: Daniel J. Chin, Jochen Deckert, Markus Hossbach, Matthias John